The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its
challenging diagnosis and management combines clinical, imagistic and biological data …

In diabetic patients, cardiomyopathy is an important cause of heart failure, but its
pathophysiology has not been completely understood thus far. Myocardial hypertrophy and …

Objectives This study examined the relationship among high-sensitivity troponin-T (hs-TnT),
outcomes, and treatment with sacubitril/valsartan in patients with heart failure (HF) and …

Heart failure with preserved ejection fraction (HFpEF) is a major clinical problem, with limited
treatments. HFpEF is characterized by a distinct, but poorly understood, skeletal muscle …

Mice with obesity and metabolic heart disease (MHD) due to a high-fat, high-sucrose diet
were treated with placebo, a clinically relevant dose of sacubitril (SAC)/valsartan (VAL), or …

Cardiovascular diseases (CVDs) still represent the greatest burden on healthcare systems
worldwide. Despite the enormous efforts over the last twenty years to limit the spread of …

The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic
strategy is one of the most significant advances in the treatment and prevention of …

Heart failure with preserved ejection fraction (HFpEF) is present in nearly half of patients
with heart failure. The prevalence of heart failure with normal or near-normal ejection …

Kidney diseases such as AKI, CKD, and GN can lead to dialysis and the need for kidney
transplantation. The pathologies for kidney diseases are extremely complex, progress at …

Since it came into being as a discipline, cardio-oncology has focused on the prevention and
treatment of cardiotoxicity induced by antitumor chemotherapy and radiotherapy. Over time …